Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench toBedside

Clinical Oncology

Volumn 26, Issue 5, 2014, Pages 250-256

  Plummer, R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chemo potentiation; DNA damage response; Poly(ADP ribose)polymerase (PARP); Radio potentiation; Synthetic lethality

Indexed keywords

ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; DNA; RADIOPROTECTIVE AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HUMAN; PRIORITY JOURNAL; RADIATION INJURY; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMORADIOTHERAPY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; RADIATION RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DNA; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-PROTECTIVE AGENTS;

EID: 84898051796     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.02.007     Document Type: Article

References (59)

1. Bernstein C., Bernstein H., Payne C.M., Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002, 511:145-178.
2. Hoeijmakers J.H. Genone maintenance mechanisms for preventing cancer. Nature 2001, 411:360-374.
3. Middleton M.R., Margison G.P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 2003, 1:37-44.
4. Bolderson E., Richard D.J., Zhou B.B., Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009, 20:6314-6320.
5. Curtin N. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin Therapeut Targets 2007, 11:783-799.
6. Hansen K., Kelly M. Review of mammalian DNA repair and translational implications. JPharmacol Exp Ther 2000, 295:1-9.
7. Christmann M., Tomicic M.T., Roos W.P., Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003, 19:3-34.
8. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
9. Wood R.D. DNA repair in eukaryotes. Ann Rev Biochem 1996, 65:135-167.
10. Lindahl T., Karran P., Wood R.D. DNA excision repair pathways. Curr Opin Genet Develop 1997, 7:158-169.
11. Lynch H.T., Smyrk T., Lynch J.F. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996, 69:38-43.
12. Fink D., Aebi S., Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998, 4:1-6.
13. Bryant H.E., Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006, 34:1685-1691.
14. Tutt A.N., Lord C.J., McCabe N., et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005, 70:139-148.
15. Chambon P., Weil J., Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophy Res Commun 1963, 11:39-44.
16. Sugimura T., Fujimura S., Hasegawa S., Kawamura Y. Polymerization of the adenosine 5'-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim Biophys Acta 1967, 138:438-441.
17. de Murcia G., Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994, 19:172-176.
18. Menissier-de Murcia J., Molinete M., Gradwohl G., Simonin F., de Murcia G. Zinc-binding domain of poly(ADP-ribose)polymerase participates in the recognition of single strand breaks on DNA. JMol Biol 1989, 210:229-233.
19. Cherney B.W., McBride O.W., Chen D.F., et al. cDNA sequence, protein structure, and chromosomal location of the human gene for poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 1987, 84:8370-8374.
20. Curtin N. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005, 7:1-20.
21. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. JNatl Cancer Inst 2004, 96:56-67.
22. Arundel-Suto C.M., Scavone S.V., Turner W.R., Suto M.J., Sebolt-Leopold J.S. Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res 1991, 126:367-371.
23. Donawho C.K., Luo Y., Luo Y., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007, 13:2728-2737.
24. Drew Y., Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Update 2009, 12:153-156.
25. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010, 10:293-301.
26. Tentori L., Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005, 52:25-33.
27. Jagtap P., Szabo C. Poly(ADP-Ribose)polymerase and the therapeautic effects of its inhibitors. Nat Rev Drug Discov 2005, 4:421-440.
28. Plummer R., Jones C., Middleton M., et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923.
29. Bignami M., O'Driscoll M., Aquilina G., Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res 2000, 462:71-82.
30. Boulton S., Pemberton L.C., Porteous J.K., et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995, 72:849-856.
31. Miknyoczki S.J., Jones-Bolin S., Pritchard S., et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003, 2:371-382.
32. Tentori L., Portarena I., Barbarino M., et al. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. Mol Pharmacol 2003, 63:192-202.
33. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
34. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
35. Khan K., Araki K., Wang D., et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010, 32:381-391.
36. Russo A.L., Kwon H.C., Burgan W.E., et al. Invitro and invivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009, 15:607-612.
37. Plummer R., Lorigan P., Steven N., et al. Aphase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013, 71:1191-1199.
38. Quinn J.A., Pluda J., Dolan M.E., et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. JClin Oncol 2002, 20:2277-2283.
39. Quinn J.A., Desjardins A., Weingart J., et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. JClin Oncol 2005, 23:7178-7187.
40. Schilsky R.L., Dolan M.E., Bertucci D., et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000, 6:3025-3031.
41. Ranson M., Middleton M.R., Bridgewater J., et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006, 12:1577-1584.
42. Isakoff S.J., Overmoyer B., Tung N.M., et al. Aphase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. JClin Oncol 2010, 28(Suppl.). abstract 1019.
43. Bedikian A.Y., Papadopoulos N.E., Kim K.B., et al. Aphase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 2009, 9:1-8.
44. Rajan A., Carter C.A., Kelly R.J., et al. Aphase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012, 18:2344-2351.
45. Kummar S., Chen A., Ji J., et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011, 71:5626-5634.
46. Khan O.A., Gore M., Lorigan P., et al. Aphase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011, 104:750-755.
47. Kummar S., Ji J., Morgan R., et al. Aphase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012, 18:1726-1734.
48. Dent R.A., Lindeman G.J., Clemons M., et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. JClin Oncol 2010, 28(Suppl.). abstract 1018.
49. O'Shaughnessy J., Osborne C., Pippen J., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. NEngl J Med 2011, 364:205-214.
50. Kopetz S., Mita M., Mok I., et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. JClin Oncol 2008, 26(Suppl.):3577.
51. Liu X., Shi Y., Maag D.X., et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012, 18:510-523.
52. Patel A.G., De Lorenzo S.B., Flatten K.S., Poirier G.G., Kaufmann S.H. Failure of iniparib to inhibit poly(ADP-ribose) polymerase invitro. Clin Cancer Res 2012, 18:1655-1662.
53. Fong P., Boss D., Yap T., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. NEngl J Med 2009, 361(2):123-134.
54. Kristeleit R.S., Shapiro G.I., LoRusso P., et al. Aphase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. JClin Oncol 2013, 31. abstract 2585.
55. Sandhu S.K., Schelman W.R., Wilding G., et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013, 14:882-892.
56. De Bono J.S., Mina L.A., Gonzalez M., et al. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. JClin Oncol 2013, 31. abstract 2580.
57. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852-861.
58. Powell C., Mikropoulos C., Kaye S.B., et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 2010, 36:566-575.
59. Harrington K.J., Billingham L.J., Brunner T.B., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer 2011, 105:628-639.